Loading patent…
AssigneediaDexus, Inc.
InventorsJackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
Estimating the term…
Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.
An isolated monoclonal antibody or antigen binding fragment thereof which binds to Ovr110, said antibody or antigen binding fragment thereof comprising:
An isolated monoclonal antibody or antigen binding fragment thereof which binds to Ovr110, said monoclonal antibody or antigen binding fragment thereof comprising:
An isolated monoclonal antibody or antigen binding fragment thereof which binds Ovr110, said monoclonal antibody or antigen binding fragment thereof comprising:
9-11. (canceled)
(canceled)
17-21. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
31-32. (canceled)
Dependencies are inferred from the claim text.